Head-to-head evidence
fluticasone furoate/vilanterol vs fluticasone propionate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor · full Asthma pipeline
fluticasone furoate/vilanterol
Marketed by GlaxoSmithKline
NCT01086384 · Phase 3 · completed
This was a randomized, triple-blind, active-controlled trial with approximately 2,019 treated participants. Its primary hard clinical endpoint—having one or more severe asthma exacerbations—favored fluticasone furoate/vilanterol and was statistically significant.
fluticasone propionate
Marketed by GlaxoSmithKline
NCT00920959 · Phase 3 · completed
The study was randomized and double-blind, included 908 participants, and compared fluticasone-based treatments with placebo. However, its primary measure was a pulmonary-function surrogate rather than a hard clinical or endoscopic outcome, and the registry does not report whether the primary comparison was met.
Next expected readout: September 2027 · NCT07664527 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/vilanterol's landscape · fluticasone propionate's landscape